Effect of tenofovir subtraction on HIV plasma viraemia, CD4+ T-cell count and resistance in a patient with baseline K65R and M184V mutations
Hsu, R.; Lanier, E.R.; Rouse, E.G.; Oie, K.L.; Pappa, K.A.; Ross, L.L.
Antiviral Therapy 13(5): 735-737
2008
ISSN/ISBN: 1359-6535 PMID: 18771059 Document Number: 617802
In vitro, the reverse transcriptase mutation K65R can simultaneously reduce drug susceptibility, replicative capacity and restrict HIV-1 replication. Here, we assessed the effect of tenofovir discontinuation for a patient receiving antiretroviral therapy whose HIV-1 had a dominant K65R/M184V genotype. Although limited by the single-case nature, the data support a hypothesis that there is no HIV viral RNA or CD4+ T-cell count benefit of taking tenofovir for experienced patients with genotypic evidence of K65R/M184V.
Document emailed within 1 workday
Related Documents
Bezemer, D.; de Ronde, A.; Prins, M.; Porter, K.; Gifford, R.; Pillay, D.; Masquelier, B.; Fleury, H.é; Dabis, F.; Back, N.; Jurriaans, S.; van der Hoek, L. 2006: Evolution of transmitted HIV-1 with drug-resistance mutations in the absence of therapy: effects on CD4+ T-cell count and HIV-1 RNA load Antiviral Therapy 11(2): 173-178Gautam, H.; Bhalla, P.; Saini, S.; Dewan, R. 2008: Correlation between baseline CD4 + T-Lymphocyte count and plasma viral load in AIDS patients and their early clinical and immunological response to HAART: a preliminary study Indian Journal of Medical Microbiology 26(3): 256-258
Kallestrup, P.; Zinyama, R.; Gomo, E.; Butterworth, A.E.; Mudenge, B.; van Dam, G.J.; Gerstoft, J.; Erikstrup, C.; Ullum, H. 2005: Schistosomiasis and HIV-1 infection in rural Zimbabwe: effect of treatment of schistosomiasis on CD4 cell count and plasma HIV-1 RNA load Journal of Infectious Diseases 192(11): 1956-1961
Smith, M.S.; Koerber, K.L.; Pagano, J.S. 1994: Long-term persistence of AZT-resistance mutations in the plasma HIV-1 of patients removed from AZT therapy Leukemia 8(Suppl 1): S179-S182
Karim, Q.Abdool.; Kharsany, A.Bm.; Frohlich, J.A.; Baxter, C.; Yende, N.; Mansoor, L.E.; Mlisana, K.P.; Maarschalk, S.; Arulappan, N.; Grobler, A.; Sibeko, S.; Omar, Z.; Gengiah, T.N.; Mlotshwa, M.; Samsunder, N.; Karim, S.S.Abdool. 2011: Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial Trials 12: 67
Todd, C.S.; Deese, J.; Wang, M.; Hubacher, D.; Steiner, M.J.; Otunga, S.; Van Damme, L. 2015: Sino-implant (II)® continuation and effect of concomitant tenofovir disoproxil fumarate-emtricitabine use on plasma levonorgestrel concentrations among women in Bondo, Kenya Contraception 91(3): 248-252
Zhang, P.-p.; Sun, J.-w.; Lu, J.-q.; Ma, L.-l.; Li, K. 2013: Correlation between baseline plasma D-dimer levels and prognosis in patients with non-smal cell lung cancer Zhonghua Zhong Liu Za Zhi 35(10): 747-750
Sheldon, J.; Camino, N.; Rodés, B.; Bartholomeusz, A.; Kuiper, M.; Tacke, F.; Núñez, M.; Mauss, S.; Lutz, T.; Klausen, G.; Locarnini, S.; Soriano, V. 2005: Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir Antiviral Therapy 10(6): 727-734
Kibler-Nockowska, M. 1981: Effect of Butecort and Flucinar ointments on various indicators of the hormonal system. I. Effect of the tested preparations on plasma ll-hydroxycorticosteroid level and absolute eosinophil count in peripheral blood Przeglad Dermatologiczny 68(2): 155-160
2002: No comparison with NRTI. Tenofovir is robust against resistance trouble MMW Fortschritte der Medizin 144 Suppl. 1: 65
Rosenmund, A.; Camponovo, F.; Köchli, H.P. 1986: The effect of hormonal contraceptives and pregnancy on iron metabolism, plasma lactoferrin levels and granulocyte count in women Schweizerische Medizinische Wochenschrift 116(41): 1411-1414
Kuznetsova, N.N.; Feoktistova, T.P.; Shapiro, N.I. 1975: The effect of cysteamine on x-ray induction of mutations resulting in resistance to 8-azaguanine in Chinese hamster cells in vitro Genetika 11(12): 56-63
Tell, G.S.; Grimm, R.H.; Vellar, O.D.; Theodorsen, L. 1985: The relationship of white cell count, platelet count, and hematocrit to cigarette smoking in adolescents: the Oslo Youth Study Circulation 72(5): 971-974
Werman, H.A.; Brown, C.G. 1986: White blood cell count and differential count Emergency Medicine Clinics of North America 4(1): 41-58
Arrivé, E.; Chaix, M-Laure.; Nerrienet, E.; Blanche, Séphane.; Rouzioux, C.; Avit, D.; Kruy, L.Sim.; McIntyre, J.; Say, L.; Gray, G.; Ekouévi, D.K.; Dabis, Fçois.; Arrivé, E.; Chaix, M-Laure.; Nerrienet, E.; Blanche, Séphane.; Rouzioux, C.; Avit, D.; Kruy, L.Sim.; McIntyre, J.; Say, L.; Gray, G.; Ekouévi, D.K.; Dabis, Fçois.; Dabis, Fçois.; Ekouévi, D.K.; Rouzioux, C.; Blanche, Séphane.; Treluyer, J-Marc.; Chaix, M-Laure.; Rey, E.; N'Dri-Yoman; Kruy, L.Sim.; Nerrienet, E.; Gray, G.; McIntyre, J.; Arrivé, E.; Hirt, Déborah.; Urien, S.; Pruvost, A.; Allou, Gérard.; A 2010: Maternal and nenonatal tenofovir and emtricitabine to prevent vertical transmission of HIV-1: tolerance and resistance Aids 24(16): 2481-2488
Tiejun, Z.; Xiaoming, Z.; Jilun, Z.; Yinghu, Z.; Yanhua, R.; Yue, C.; Weiming, G.; Tao, Z.; Qingwu, J. 2009: Fluoroquinolone resistance among Neisseria gonorrhoeae isolates from Shanghai, China: detection of quinolone resistance-determining region mutations Indian Journal of Medical Research 129(6): 701-706
Courcambeck, J.ér.ôm.; Bouzidi, M.; Perbost, R.ég.; Jouirou, B.; Amrani, N.; Cacoub, P.; Pèpe, G.ér.; Sabatier, J.-M.; Halfon, P. 2006: Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations Antiviral Therapy 11(7): 847-855
Snopková, S.; Havlíčková, K.ři.; Husa, P. 2016: Tenofovir alafenamide fumarate - a new generation of tenofovir Klinicka Mikrobiologie a Infekcni Lekarstvi 22(3): 111-117
Mouroux, M.; Descamps, D.; Izopet, J.; Yvon, A.; Delaugerre, C.; Matheron, S.; Coutellier, A.; Valantin, M.A.; Bonmarchand, M.; Agut, H.; Massip, P.; Costagliola, D.; Katlama, C.; Brun-Vezinet, F.; Calvez, V. 2001: Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus lamivudine combination therapy Antiviral Therapy 6(3): 179-183
Baeten, J.M.; Donnell, D.; Mugo, N.R.; Ndase, P.; Thomas, K.K.; Campbell, J.D.; Wangisi, J.; Tappero, J.W.; Bukusi, E.A.; Cohen, C.R.; Katabira, E.; Ronald, A.; Tumwesigye, E.; Were, E.; Fife, K.H.; Kiarie, J.; Farquhar, C.; John-Stewart, G.; Kidoguchi, L.; Coombs, R.W.; Hendrix, C.; Marzinke, M.A.; Frenkel, L.; Haberer, J.E.; Bangsberg, D.; Celum, C. 2014: Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial Lancet. Infectious Diseases 14(11): 1055-1064